For background on the Fabrazyme case, see: https://www.keionline.org/fabrazyme
The following statements were made today by civil society on the NIH rejection of the Fabrazyme March-in Request Petition. Contact Judit Rius at judit.rius@keionline.org if your organization would like to submit an statement.
Statement by James Love, Director of Knowledge Ecology International (KEI) (Contact: 1.202.361.3040)
Continue Reading →
On December 19, 2007, the The Energy Independence and Security Act of 2007 was enacted as Public Law 110-140. The Act created two new innovation inducement prizes to stimulate innovation in the field of energy:
- The H-Prize, which is designed to advance the research, development, demonstration, and commercial application of hydrogen energy technologies.
- The Bright Tomorrow Lighting Prizes, which deal with energy efficient solid state lighting.
Continue Reading →
Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 KEI Research Note 2010:4 August 12, 2010 Anne Mira Guha Prices for Abbott’s Norvir (generic name Ritonavir) as a Standalone Product in 2010 1. Introduction Ritonavir is… Continue Reading →
Written submission U.S. Senate Committee on Health, Education, Labor, and Pensions (HELP) Hearing on Treating Rare and Neglected Pediatric Diseases: Promoting the Development of New Treatments and Cures, On the topic of Direct funding, subsidies and incentives for the development… Continue Reading →